HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.
Bart PA, Huang Y, Karuna ST, Chappuis S, Gaillard J, Kochar N, Shen X, Allen MA, Ding S, Hural J, Liao HX, Haynes BF, Graham BS, Gilbert PB, McElrath MJ, Montefiori DC, Tomaras GD, Pantaleo G, Frahm N.
Bart PA, et al. Among authors: huang y.
J Clin Invest. 2014 Nov;124(11):4843-56. doi: 10.1172/JCI75894. Epub 2014 Oct 1.
J Clin Invest. 2014.
PMID: 25271627
Free PMC article.
Clinical Trial.